STOP-ACEi Newsletter

Issue 1	December 2013

Full Title: Multi-centre Randomised Controlled Trial of Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) withdrawal in advanced renal disease

Short Title: STOP-ACEi

Welcome to the first issue of the STOP-ACEi Newsletter!

Applications are currently progressing with the relevant ethics, NHS and regulatory bodies and we aim to start recruitment to STOP-ACEi in April 2014. The Leeds East Research Ethics Committee (REC) met on 3rd December 2013 to consider the study.

Trial Design:

An investigator-led, multi-centre, open-label, randomised controlled clinical trial.

Trial Aim:

To test the hypothesis that stopping ACEi/ARB treatment, compared with continuing on these treatments, improves or stabilises renal function in patients with progressive stage 4 or 5 chronic kidney disease (CKD).

Population: 410 patients with stage 4 or 5 CKD that have progressive deterioration in renal function (fall in eGFR of >2 mL/min over last 12-24 months) and are currently receiving ACEi/ARB therapy.

Hull and East Yorkshire Hospitals NHS Trust

MRC Medical Research Council

NHS National Institute for Health Research

UNIVERSITY OF BIRMINGHAM

BIRMINGHAM CLINICAL TRIALS UNIT

Message from the Chief Investigator

Dear Colleagues,

I am absolutely delighted that after over two years work since the genesis of the STOP ACEi trial, which is supported by the MRC/NIHR, we have progressed to seeking favourable ethical and MHRA reviews. Once these have been completed we will be able to commence setting up participating centres.

We plan to start recruitment mid-2014. As we enter this exciting phase I greatly look forward to working with you over the coming years to deliver the answers required to the important questions we are addressing.

We are keen to recruit further centres, so please spread the word amongst your colleagues locally.

Please feel free to contact me (sunil.bhandari@hey.nhs.uk) if you have any questions regarding the study.

Best wishes,

Prof Sunil Bhandari

Participating in STOP-ACEi

Recruitment to the STOP-ACEi trial will take place in several research sites across the UK, with 4 main recruitment centres; Hull, Sheffield, Leicester and Birmingham. Several other sites have also expressed an interest in STOP-ACEi and we are keen to add further recruitment sites.

Applications are currently in progress to gain all the necessary NHS, ethics and regulatory permissions to allow the study to begin at each site. The Trial Coordinator, Marie Valente, will be in touch with site staff shortly to ask for details about your centre's participation in the study and request your contact details, CVs and copies of GCP certificates to be able to complete the required steps. Please look out for a Practical Arrangements Form to complete and return to the STOP-ACEi Trials Office.

We have already been in contact with the following sites regarding STOP-ACEi and are keen to involve further sites:

Hull Royal Infirmary	Leicester General Hospital
Queen Elizabeth Hospital, Birmingham	Northern General Hospital, Sheffield
Doncaster Royal Infirmary	Royal Preston Hospital
Lister Hospital, Stevenage	Birmingham Heartlands Hospital
Kent & Canterbury Hospital	Salford Royal Hospital
Royal Free Hospital, London	King's College Hospital, London
Western Infirmary, Glasgow	Sunderland Royal Hospital
Hammersmith Hospital, London	

Study timelines

We aim to start recruitment in April 2014. There will be a 2 year recruitment period until April 2016 and follow-up will continue for three further years until April 2019. We hope to publish the results of the trial in October 2019.



Study schema



Eligibility criteria

Inclusion criteria:

- Aged ≥18 years (male or female);
- CKD stage 4 or 5 (eGFR <30mls/minute using the MDRD equation) and not on dialysis therapy;
- Progressive deterioration in renal function (fall in eGFR of >2ml/min/year over previous 12-24 months, a tool to calculate this will be provided);
- Treatment with either an ACEi or ARB or a combination of both for >6 months with at least 25% of the maximum recommended daily dose on the day of consent;
- Resting blood pressure (BP) ≤160/90 mmHg when measured in accordance with British Hypertension Society guidelines in clinic or recent home blood pressure readings within the previous month or a 24h ambulatory blood pressure measurement within in the last 3 months are acceptable.
- At least 3 months of specialist renal follow-up at the time of entry into the trial;
- Written, signed informed consent to the trial.

Exclusion Criteria:

- Aged <18 years;
- Uncontrolled hypertension (>160/90mmHg) or requirement for 5 or more agents to control BP;
- Undergoing dialysis therapy;
- Any condition which, in the opinion of the investigator, makes the participant unsuitable for trial entry due to prognosis/terminal illness with a projected survival of less than 12 months;
- History of myocardial infarction or stroke in preceding 3 months;
- Participation in an interventional research study in preceding 6 weeks;
- Pregnancy, confirmed by positive pregnancy test, or breastfeeding;
- Inability to provide informed consent (e.g. due to cognitive impairment);
- Immune mediated renal disease requiring disease-specific treatment;
- Known drug or alcohol abuse;
- Inability to comply with the trial schedule and follow-up.

STOP-ACEi study details:	
Sponsor: Hull and East Yorkshire NHS Foundation Trust. Ref: R1578	**Funding:** The NIHR/MRC Efficacy and Mechanism Evaluation (EME) Programme. Ref: 11/30/07
EudraCT no: 2013-003798-82 **ISRCTN no:** TBC **REC ref no:** 13/YH/0394 **IRAS/CSP ref no:** 138827	**Portfolio adoption:** As an NIHR funded study, STOP-ACEi will be adopted onto the NIHR CRN Portfolio.

The STOP-ACEi study team are always here to help

For further information about the STOP-ACEi study, please contact us:

STOP-ACEi Chief Investigator: Prof Sunil Bhandari, Hull and East Yorkshire Hospitals NHS Trust, sunil.bhandari@hey.nhs.uk	**STOP-ACEi Trials Coordinator:** Marie Valente, STOP-ACEi Study Office, Birmingham Clinical Trials Unit
STOP-ACEi Trials Office: **Website:** www.birmingham.ac.uk/stopacei (Website is currently in development) **E-mail:** StopACEi@trials.bham.ac.uk **Telephone:** (0121) 415 9132 **Fax:** (0121) 415 9135	**Randomisation:** **Website:** www.trials.bham.ac.uk/stopacei (Website is currently in development) **Telephone:** 0800 953 0274 (Available 9am-5pm, Monday – Friday)
Postal address: STOP-ACEi Study Office, Birmingham Clinical Trials Unit (BCTU), College of Medical and Dental Sciences, Robert Aitken Institute, University of Birmingham, Birmingham, B15 2TT	**Christmas closure:** Please note that the STOP-ACEi study office at BCTU will be closed over the Christmas break: from 5pm Friday 20th December 2013 until 9am Thursday 2nd January 2014

Thank you for taking the time to read the first STOP-ACEi Newsletter

We look forward to setting up the trial at your site!

We would like to take this opportunity to wish you a very happy Christmas and New Year!